Is Bezotevan available in China? when

Belzutifan As an epoch-making targeted drug, with its uniqueHIF-2α inhibitory mechanism, Belzutifan is regarded as a breakthrough drug in the treatment of VHL-related tumors. For a long time, this type of disease has lacked systematic treatment in China due to its complex mechanisms and limited available drugs. In November 2024, China's National Medical Products Administration (NMPA) officially approved the marketing application for bezutivan. This news marks that domestic patients can finally legally obtain this new global anti-cancer drug.

The application for this approval was led by Merck & Co., and the drug name is "Bestifan Tablets", which is currently the only HIF-2α inhibitor on the market in the world. The indications approved by the NMPA include the treatment of von Hippel-Lindau disease (VHL)-related renal cell carcinoma (RCC), central nervous system hemangioblastoma, and pancreatic neuroendocrine tumors. This approval not only fills the gap in domestic drug treatment for VHL-related diseases, but also brings more precise and targeted treatment options to patients.

It is worth noting that the launch of bezutivan is based on a large amount of international research. In particular, the in-depth understanding of the etiological mechanism of VHL has prompted scientists to focus on the HIF pathway to develop this specific molecular inhibitor. Prior to this, VHL patients usually relied on surgery to control tumor progression, and were troubled by repeated recurrences and reduced quality of life. The emergence of bestivan changed this situation, making long-term disease management possible, reducing the frequency of surgery for patients, and delaying the growth of tumors.

Although Bezutivan has been approved for marketing in China, it is still in the initial stage of market development. Pharmacies in many places have not yet officially put it on sale, and clinical use in hospitals also needs to wait for relevant channels to be opened. Therefore, the availability of medicines in the short term is still relatively limited, especially in grassroots or non-large urban hospitals that are not yet fully covered.

Reference materials:https://www.welireg.com/